To amend the Federal Food, Drug, and Cosmetic Act to encourage the development of vaccines to prevent, treat, or mitigate opioid, cocaine, methamphetamine, or alcohol use disorder, to establish an x-prize for the development of such a vaccine, and for other purposes.

This bill amends FDA regulations to accelerate the development of vaccines for opioid, cocaine, methamphetamine, and alcohol use disorders. It designates such vaccines as "breakthrough therapies" and "fast track products" to speed up FDA review, with these provisions expiring after 10 years. Additionally, it creates a $1 billion "Vaccine X-Prize" for the first developer whose approved vaccine is mass-produced for these conditions. The bill directly affects pharmaceutical companies developing these vaccines and the FDA’s review process, with no cost or tax changes specified.